All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The EMA grants crenolanib Orphan Drug Designation for AML
In November 2016, the European Medicines Agency’s (EMAs) Committee for Orphan Medicinal Products (COMP) granted Orphan Drug Designation for crenolanib for the treatment of Acute Myeloid Leukemia (AML).
FMS like Tyrosine Kinase 3 (FLT3) mutations with Internal Tandem Duplications (ITD) occurs in approximately 30% of AML patients. These mutations often lead to poor prognosis and disease relapse in AML patients (Zimmerman et al., 2013).
Crenolanib is a novel Tyrosine Kinase Inhibitor (TKI) that was initially developed as a selective and potent inhibitor for Platelet-Derived Growth Factor Receptor (PDGFR) α and β but it also has a high affinity for FLT3 (Zimmerman et al., 2013). Crenolanib binds to and inhibits both wild-type and mutated forms of FLT3, which can lead to the inhibition of FLT3-related signal transduction pathways.
Crenolanib is currently being explored in multiple trials for newly diagnosed (NCT02283177) and relapsed/refractory (NCT02298166, NCT02400281, NCT01657682) AML patients with or without FLT3 mutations.
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?